Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.70 |
| ▸ | ITK | Q08881 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TTK | P33981 | 4/20 | 0.56 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12281007 | 0.87 | TTK (0.79) | AURKATTK | |
| SCHEMBL5381231 | 0.86 | AURKA (0.59) | NAMPTITKROCK2ROCK1MAPK1 | |
| SCHEMBL758975 | 0.86 | ROCK2 (0.61) | NAMPTITKROCK2ROCK1AURKA | |
| SCHEMBL5800969 | 0.84 | TTK (0.59) | NAMPTITKROCK2ROCK1MAPK1 | |
| SCHEMBL14404250 | 0.84 | ITK (0.60) | NAMPTITKROCK2ROCK1MAPK1 | |
| SCHEMBL20379744 | 0.82 | NAMPT (1.00) | NAMPTROCK2ROCK1MAPK1MAPK3 | |
| SCHEMBL29882418 | 0.82 | NAMPT (1.00) | NAMPTROCK2ROCK1MAPK1MAPK3 | |
| SCHEMBL5387657 | 0.81 | AURKA (0.54) | NAMPTITKROCK2ROCK1MAPK1 | |
| SCHEMBL5387211 | 0.80 | AURKA (0.53) | NAMPTITKROCK2ROCK1MAPK1 | |
| SCHEMBL8260089 | 0.80 | TTK (0.69) | ITKAURKATTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | NAMPT 257/4885ITK 1619/4885ROCK2 3219/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | NAMPT 257/4885ITK 1619/4885ROCK2 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.